Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Cash and cash equivalents of approximately $11.5 million as of October 31, 2023

Special meeting of stockholders on November 16 seeking stockholder approval of the Dissolution and Plan of Dissolution

Read more at globenewswire.com